Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.64 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 6/20 | 0.55 |
| ▸ | AURKA | O14965 | 5/20 | 0.55 |
| ▸ | MET | P08581 | 5/20 | 0.55 |
| ▸ | TEK | Q02763 | 5/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | LYN | P07948 | 1/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29535684 | 1.00 | PDGFRB (0.64) | PDGFRBPDGFRAKDRAURKAMET | |
| Hydrochloric Acid SCHEMBL27894607 | 0.99 | PDGFRB (0.62) | PDGFRBPDGFRAKDRAURKAMET | |
| SCHEMBL30152477 | 0.94 | PDGFRB (0.64) | PDGFRBPDGFRAKDRAURKAMET | |
| SCHEMBL28839474 | 0.94 | PDGFRB (0.64) | PDGFRBPDGFRAKDRAURKAMET | |
| SCHEMBL30229311 | 0.94 | PDGFRB (0.64) | PDGFRBPDGFRAKDRAURKAMET | |
| SCHEMBL29372253 | 0.93 | PDGFRB (0.56) | PDGFRBPDGFRAKDRAURKAMET | |
| SCHEMBL23640270 | 0.87 | PDGFRB (0.66) | PDGFRBPDGFRAKDRAURKAKDM4E | |
| SCHEMBL29488239 | 0.87 | PDGFRB (0.66) | PDGFRBPDGFRAAURKAKDM4EALDH1A1 | |
| SCHEMBL30448935 | 0.85 | PDGFRB (0.64) | PDGFRBPDGFRAAURKAKDM4EALDH1A1 | |
| SCHEMBL30152708 | 0.85 | PDGFRB (0.49) | PDGFRBPDGFRAKDRAURKAMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115298198-A | Novel compounds and compositions for targeted therapy of kidney-related cancers | 上海盟科药业股份有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-107266363-A | Methanesulfonic acid pleasure is cut down for the preparation method of Buddhist nun's impurity of the drug | 杭州华东医药集团新药研究院有限公司 | 2017-10-20 | — | — | CN | claimed |
| US-20260083724-A1 | COMPOUNDS TARGETING PAX3::FOXO1 FUSION PROTEIN | GEORGETOWN UNIVERSITY (US) | 2026-03-26 | — | — | US | disclosed |
| US-12391666-B2 | Indoline-1-formamide compound, preparation method therefor, and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2025-08-19 | — | — | US | disclosed |
| CN-116751162-B | Quinoline compound, preparation method thereof, pharmaceutical composition and medical application | 中国人民解放军军事科学院军事医学研究院 | 2025-02-28 | — | — | CN | disclosed |
| CN-117865887-A | Preparation method of lenvatinib mesylate intermediate | 山东鲁抗医药股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117624044-A | Preparation method of lenvatinib | 山东新时代药业有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2024-02-08 | — | — | US | disclosed |
| CN-117321036-A | phenyl-O-quinoline, quinazoline, thienopyridine, thienopyrimidine, pyrrolopyridine, pyrrolopyrimidine compounds having anticancer activity | 成都安泰康赛生物科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-116751161-A | Quinoline compound, preparation method thereof, pharmaceutical composition and medical application | 中国人民解放军军事科学院军事医学研究院 | 2023-09-15 | — | — | CN | disclosed |
| CN-116751162-A | Quinoline compound, preparation method thereof, pharmaceutical composition and medical application | 中国人民解放军军事科学院军事医学研究院 | 2023-09-15 | — | — | CN | disclosed |
| CN-113924288-A | Quinolyl-containing compound, pharmaceutical composition and application thereof | 北京普祺医药科技有限公司 | 2022-01-11 | — | — | CN | disclosed |
| US-20210322404-A1 | FGFR REGULATION FOR THE TREATMENT OF VIRAL INFECTIONS | ETH ZURICH (CH) | 2021-10-21 | — | — | US | disclosed |
| CN-110003219-A | Pyrazolo [1,5A] pyrimidine and thieno [3,2B] pyrimidine derivatives as IRAK4 regulator | 弗·哈夫曼-拉罗切有限公司 | 2019-07-12 | — | — | CN | disclosed |
| CN-109851556-A | Logical sequence cuts down the preparation method for Buddhist nun or its mesylate drug impurity | 扬子江药业集团有限公司 | 2019-06-07 | — | — | CN | disclosed |
| CN-105367577-B | Pyrazolo [1,5A] pyrimidine and thieno [3,2B] pyrimidine derivatives as IRAK4 regulator | 弗·哈夫曼-拉罗切有限公司 | 2019-04-23 | — | — | CN | disclosed |
| CN-107305202-A | The HPLC methods and impurity that analysis methanesulfonic acid pleasure is cut down for Buddhist nun and its preparation impurity make the purposes of reference standard | 北京睿创康泰医药研究院有限公司 | 2017-10-31 | — | — | CN | disclosed |
| CN-107266363-A | Methanesulfonic acid pleasure is cut down for the preparation method of Buddhist nun's impurity of the drug | 杭州华东医药集团新药研究院有限公司 | 2017-10-20 | — | — | CN | disclosed |
| CN-104876864-B | A kind of pleasure cuts down the preparation method for Buddhist nun | 北京康立生医药技术开发有限公司 | 2017-03-08 | — | — | CN | disclosed |
| CN-105801481-A | Lenvatinib synthesizing method | 湖南欧亚生物有限公司 | 2016-07-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391666-B2 | Indoline-1-formamide compound, preparation method therefor, and medical use thereof | FLT1, KDR, TEK | PDGFRB 38/4885PDGFRA 25/4885KDR 2/4885 |
| US-20260083724-A1 | COMPOUNDS TARGETING PAX3::FOXO1 FUSION PROTEIN | PAX3, FOXO1, PAXBP1 | PDGFRB 2327/4885PDGFRA 2497/4885KDR 1973/4885 |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | PDGFRB 327/4885PDGFRA 564/4885KDR 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.